Literature DB >> 26677864

MicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease.

Ronak Lakhia1, Sachin Hajarnis1, Darren Williams1, Karam Aboudehen2, Matanel Yheskel1, Chao Xing3, Mark E Hatley4, Vicente E Torres5, Darren P Wallace6, Vishal Patel7.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), one of the most common monogenetic disorders, is characterized by kidney failure caused by bilateral renal cyst growth. MicroRNAs (miRs) have been implicated in numerous diseases, but the role of these noncoding RNAs in ADPKD pathogenesis is still poorly defined. Here, we investigated the role of miR-21, an oncogenic miR, in kidney cyst growth. We found that transcriptional activation of miR-21 is a common feature of murine PKD. Furthermore, compared with renal tubules from kidney samples of normal controls, cysts in kidney samples from patients with ADPKD had increased levels of miR-21. cAMP signaling, a key pathogenic pathway in PKD, transactivated miR-21 promoter in kidney cells and promoted miR-21 expression in cystic kidneys of mice. Genetic deletion of miR-21 attenuated cyst burden, reduced kidney injury, and improved survival of an orthologous model of ADPKD. RNA sequencing analysis and additional in vivo assays showed that miR-21 inhibits apoptosis of cyst epithelial cells, likely through direct repression of its target gene programmed cell death 4 Thus, miR-21 functions downstream of the cAMP pathway and promotes disease progression in experimental PKD. Our results suggest that inhibiting miR-21 is a potential new therapeutic approach to slow cyst growth in PKD.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  cell death; miR-21; microRNAs; polycystic kidney disease

Mesh:

Substances:

Year:  2015        PMID: 26677864      PMCID: PMC4978047          DOI: 10.1681/ASN.2015060634

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  56 in total

Review 1.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

2.  Caspase-3 gene deletion prolongs survival in polycystic kidney disease.

Authors:  Yunxia Tao; Iram Zafar; Jun Kim; Robert W Schrier; Charles L Edelstein
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

Review 3.  MicroRNAs in stress signaling and human disease.

Authors:  Joshua T Mendell; Eric N Olson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 4.  1992 Homer Smith Award. Fluid secretion, cellular proliferation, and the pathogenesis of renal epithelial cysts.

Authors:  J J Grantham
Journal:  J Am Soc Nephrol       Date:  1993-06       Impact factor: 10.121

Review 5.  Advances in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Vishal Patel; Renuka Chowdhury; Peter Igarashi
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-03       Impact factor: 2.894

6.  Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.

Authors:  Olubunmi Afonja; Dominique Juste; Sharmistha Das; Sachiko Matsuhashi; Herbert H Samuels
Journal:  Oncogene       Date:  2004-10-21       Impact factor: 9.867

7.  MicroRNAs and Polycystic Kidney Disease.

Authors:  Lama Noureddine; Sachin Hajarnis; Vishal Patel
Journal:  Drug Discov Today Dis Models       Date:  2013

8.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

9.  Tissue-specific regulation of the mouse Pkhd1 (ARPKD) gene promoter.

Authors:  Scott S Williams; Patricia Cobo-Stark; Sachin Hajarnis; Karam Aboudehen; Xinli Shao; James A Richardson; Vishal Patel; Peter Igarashi
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-04

10.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data.

Authors:  Jun-Hao Li; Shun Liu; Hui Zhou; Liang-Hu Qu; Jian-Hua Yang
Journal:  Nucleic Acids Res       Date:  2013-12-01       Impact factor: 16.971

View more
  30 in total

1.  Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models.

Authors:  Caroline Weydert; Jean-Paul Decuypere; Humbert De Smedt; Peter Janssens; Rudi Vennekens; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-09-13       Impact factor: 3.714

Review 2.  Modulation of polycystic kidney disease by non-coding RNAs.

Authors:  Harini Ramalingam; Matanel Yheskel; Vishal Patel
Journal:  Cell Signal       Date:  2020-01-23       Impact factor: 4.315

3.  Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2WS25/- mouse model of autosomal dominant polycystic kidney disease.

Authors:  Md Monirujjaman; Harold M Aukema
Journal:  J Nephrol       Date:  2019-01-22       Impact factor: 3.902

Review 4.  The role of PPARα in autosomal dominant polycystic kidney disease.

Authors:  Ronak Lakhia
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

Review 5.  Noncoding RNA and epigenetic gene regulation in renal diseases.

Authors:  Satya K Kota; Savithri B Kota
Journal:  Drug Discov Today       Date:  2017-05-06       Impact factor: 7.851

Review 6.  The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Maria Fragiadaki; Fiona M Macleod; Albert C M Ong
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

Review 7.  Therapeutic microRNAs in polycystic kidney disease.

Authors:  Matanel Yheskel; Vishal Patel
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-07       Impact factor: 2.894

8.  PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Authors:  Ronak Lakhia; Matanel Yheskel; Andrea Flaten; Ezekiel B Quittner-Strom; William L Holland; Vishal Patel
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-13

Review 9.  MicroRNAs and drug-induced kidney injury.

Authors:  Mira Pavkovic; Vishal S Vaidya
Journal:  Pharmacol Ther       Date:  2016-04-25       Impact factor: 12.310

10.  Suppression of microRNA Activity in Kidney Collecting Ducts Induces Partial Loss of Epithelial Phenotype and Renal Fibrosis.

Authors:  Sachin Hajarnis; Matanel Yheskel; Darren Williams; Thomas Brefort; Bob Glaudemans; Huguette Debaix; Michel Baum; Olivier Devuyst; Vishal Patel
Journal:  J Am Soc Nephrol       Date:  2017-10-11       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.